| First Author | Centomo ML | Year | 2022 |
| Journal | Cancers (Basel) | Volume | 14 |
| Issue | 24 | PubMed ID | 36551740 |
| Mgi Jnum | J:332249 | Mgi Id | MGI:7411524 |
| Doi | 10.3390/cancers14246255 | Citation | Centomo ML, et al. (2022) An Immunocompetent Environment Unravels the Proto-Oncogenic Role of miR-22. Cancers (Basel) 14(24) |
| abstractText | MiR-22 was first identified as a proto-oncogenic microRNA (miRNA) due to its ability to post-transcriptionally suppress the expression of the potent PTEN (Phosphatase And Tensin Homolog) tumor suppressor gene. miR-22 tumorigenic role in cancer was subsequently supported by its ability to positively trigger lipogenesis, anabolic metabolism, and epithelial-mesenchymal transition (EMT) towards the metastatic spread. However, during the following years, the picture was complicated by the identification of targets that support a tumor-suppressive role in certain tissues or cell types. Indeed, many papers have been published where in vitro cellular assays and in vivo immunodeficient or immunosuppressed xenograft models are used. However, here we show that all the studies performed in vivo, in immunocompetent transgenic and knock-out animal models, unanimously support a proto-oncogenic role for miR-22. Since miR-22 is actively secreted from and readily exchanged between normal and tumoral cells, a functional immune dimension at play could well represent the divider that allows reconciling these contradictory findings. In addition to a critical review of this vast literature, here we provide further proof of the oncogenic role of miR-22 through the analysis of its genomic locus vis a vis the genetic landscape of human cancer. |
